English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Schizophrenia is a serious and often devastating disease, affecting approximately 1% of worldwide population. Animal models represent a suitable way for investigating serious brain diseases in preclinical research. Animal models of schizophrenia can be generally divided into several categories that include pharmacological, genetic and neurodevelopmental models. Pharmacological models are usually based on application of specific receptor ligands for neurotransmitters. Genetic models are created by genetic manipulations (mutations; often in laboratory mice). Neurodevelopmental models are induced by manipulations in early stages of life of the laboratory animal. They are manifested later in juvenile or adult age by phenotypes that are similar to schizophrenia symptoms. This review summarizes and discusses pharmacological models of schizophrenia based on application of NMDA receptor antagonists; furthermore, the study focuses on selected genetic and neurodevelopmental models.

Animal Models of Schizophrenia with a Focus on Models Targeting NMDA Receptors